Antibiotics, the microbiome and gastrointestinal cancers: A causal interference?


Journal

Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133

Informations de publication

Date de publication:
12 2022
Historique:
received: 20 09 2022
revised: 03 10 2022
accepted: 08 10 2022
pubmed: 10 11 2022
medline: 20 12 2022
entrez: 9 11 2022
Statut: ppublish

Résumé

Our understanding of the gut microbiota has significantly evolved over the last two decades. Advances in the analysis of the gut microbiome continues to reveal complex microbial communities and discoveries about their role in health and diseases, including cancer development, are continuously growing. In addition, research has demonstrated that the use of antibiotics can modulate the gut microbiota composition negatively and influence cancer treatment outcomes, suggesting that antibiotics should be avoided if possible. In this article, we review the role of the gut microbiota in the formation of GI cancers. We show that specific bacterial populations can positively or negatively affect cancer formation with specific attention given to gastric and colorectal cancer. We also review the role of microbial-targeted therapies on cancer treatment outcomes.

Identifiants

pubmed: 36351361
pii: S1471-4892(22)00142-4
doi: 10.1016/j.coph.2022.102315
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102315

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Daryl Ramai (D)

Division of Gastroenterology and Hepatology, University of Utah Health, Salt Lake City, UT, USA.

Massimiliano Salati (M)

Department of Oncology and Hematology, Division of Oncology, University Hospital of Modena, Modena, Italy.

Giulia Pomati (G)

Department of Molecular Medicine, Sapienza University of Rome, Italy.

Chiara Amoroso (C)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Antonio Facciorusso (A)

Gastroenterology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Andrea Botticelli (A)

Department of Radiological, Oncological, Pathological Department, La Sapienza, University of Rome, Policlinico Umberto I, Rome, Italy.

Michele Ghidini (M)

Division of Medical Oncology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. Electronic address: michele.ghidini@policlinico.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH